127 related articles for article (PubMed ID: 38930015)
1. Sodium-Glucose Cotransporter Type 2 Inhibitors Use in Elderly Polypathological Patients with Acute Heart Failure: PROFUND-IC Registry.
Guzmán-Carreras A; Vellisca-González AM; Molina-Puente JI; García-Alonso R; Paz-Cabezas M; Sánchez-Sauce B; Aguilar-Rodríguez F; Iguarán-Bermúdez MDR; Andrès E; Lorenzo-Villalba N; Méndez-Bailón M
J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38930015
[No Abstract] [Full Text] [Related]
2. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
[TBL] [Abstract][Full Text] [Related]
3. Cardio-renal-metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort.
Beles M; Masuy I; Verstreken S; Bartunek J; Dierckx R; Heggermont W; Oeste C; De Boeck M; Fovel I; Maris M; Vermeulen Z; Vanderheyden M
ESC Heart Fail; 2023 Aug; 10(4):2269-2280. PubMed ID: 37095712
[TBL] [Abstract][Full Text] [Related]
4. Association of sodium-glucose cotransporter 2 inhibitors with post-discharge outcomes in patients with acute heart failure with type 2 diabetes: a cohort study.
Park S; Jeong HE; Lee H; You SC; Shin JY
Cardiovasc Diabetol; 2023 Jul; 22(1):191. PubMed ID: 37507739
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
Mentz RJ; Brunton SA; Rangaswami J
Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of the PROFUND Index for 30-Day Mortality in Acute Heart Failure.
Méndez-Bailón M; Iguarán-Bermúdez R; López-García L; Sánchez-Sauce B; Pérez-Mateos P; Barrado-Cuchillo J; Villar-Martínez M; Fernández-Castelao S; García-Klepzig JL; Fuentes-Ferrer ME; García-García A; Vilacosta I; de Miguel-Yanes JM; Casas-Rojo JM; Calvo-Manuel E; Andres E; Lorenzo-Villalba N; On Behalf Of The Heart Failure And Pluripathology Groups From The Spanish National Society Of Internal Medicine
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833368
[No Abstract] [Full Text] [Related]
7. Clinical Characteristics and Prognostic Impact of Short Physical Performance Battery in Hospitalized Patients with Acute Heart Failure-Results of the PROFUND-IC Registry.
López-García L; Lorenzo-Villalba N; Molina-Puente JI; Kishta A; Sanchez-Sauce B; Aguilar-Rodriguez F; Bernanbeu-Wittel M; Muñoz-Rivas N; Soler-Rangel L; Fernández-Carmena L; Andrès E; Deodati F; Trapiello-Valbuena F; Casasnovas-Rodríguez P; López-Reboiro ML; Méndez-Bailon M
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762915
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose cotransporter 2 inhibitors are associated with reduced risk of mortality and readmissions in heart failure.
Karlström P; Pivodic A; Dahlström U; Fu M
ESC Heart Fail; 2024 Feb; 11(1):327-337. PubMed ID: 38012065
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose cotransporter-2 inhibitors improve cardiovascular outcomes post-acute coronary syndrome complicated by acute heart failure.
Rahhal A; Hamamyh T; Chapra A; Zaza KJ; Najim M; Hemadneh M; Faraj H; Kanjo W; Yasin A; Toba H; Mohammed W; Hamad MK; Al-Tikrety N; Baraa Habib M; Awaisu A; Mahfouz A; Alyafei S; Arabi AR; Patel A; Al-Hijji M
Front Cardiovasc Med; 2024; 11():1383669. PubMed ID: 38832317
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose co-transporter 2 inhibitors in acute heart failure: real-world prescription trends and outcomes analysis.
Mizobuchi S; Saito Y; Kitano D; Toyama K; Miyagawa M; Koyama Y; Fujito H; Kojima K; Murata N; Fukamachi D; Okumura Y
ESC Heart Fail; 2024 Feb; 11(1):410-421. PubMed ID: 38017700
[TBL] [Abstract][Full Text] [Related]
11. The midrange left ventricular ejection fraction (LVEF) is associated with higher all-cause mortality during the 1-year follow-up compared to preserved LVEF among real-world patients with acute heart failure: a single-center propensity score-matched analysis.
Borovac JA; Novak K; Bozic J; Glavas D
Heart Vessels; 2019 Feb; 34(2):268-278. PubMed ID: 30159656
[TBL] [Abstract][Full Text] [Related]
12. The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: A meta-analysis of randomized controlled trials.
Fan G; Guo DL
Eur J Intern Med; 2023 Aug; 114():49-57. PubMed ID: 37062643
[TBL] [Abstract][Full Text] [Related]
13. Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.
Gupta K; Spertus JA; Birmingham M; Gosch KL; Husain M; Kitzman DW; Pitt B; Shah SJ; Januzzi JL; Lingvay I; Butler J; Kosiborod M; Lanfear DE
Circulation; 2023 Jul; 148(3):220-228. PubMed ID: 37191040
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of the PROFUND Index on One Year Mortality in Acute Heart Failure: Results from the RICA Registry.
Méndez-Bailon M; Iguarán-Bermudez R; Formiga-Pérez F; Arévalo Lorido JC; Suárez-Pedreira I; Morales-Rull JL; Serrado-Iglesias A; Llacer-Iborra P; Ormaechea-Gorricho G; Carrasco-Sánchez FJ; Casado-Cerrada J; Andrès E; Diez-Manglano J; Lorenzo-Villalba N; Montero-Pérez-Barquero M
J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407495
[TBL] [Abstract][Full Text] [Related]
15. Contemporary Use of Sodium Glucose Co-Transporter 2 Inhibitors in Hospitalized Heart Failure Patients: A "Real-World" Experience.
Xanthopoulos A; Katsiadas N; Giamouzis G; Vangelakou K; Balaskas D; Papamichalis M; Bourazana A; Chrysakis N; Kiokas S; Kourek C; Briasoulis A; Skopeliti N; Makaritsis KP; Parissis J; Stefanidis I; Magouliotis D; Athanasiou T; Triposkiadis F; Skoularigis J
J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38930091
[No Abstract] [Full Text] [Related]
16. Association between anemia and outcome in patients hospitalized for acute heart failure syndromes: findings from Beijing Acute Heart Failure Registry (Beijing AHF Registry).
Ye SD; Wang SJ; Wang GG; Li L; Huang ZW; Qin J; Li CS; Yu XZ; Shen H; Yang LP; Fu Y; Zheng YA; Zhao B; Yu DM; Qin FJ; Zhou DG; Li Y; Liu FJ
Intern Emerg Med; 2021 Jan; 16(1):183-192. PubMed ID: 32356137
[TBL] [Abstract][Full Text] [Related]
17. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
[TBL] [Abstract][Full Text] [Related]
18. Safety of sodium-glucose cotransporter 2 inhibitors drugs among heart failure patients: a systematic review and meta-analysis.
Soleimani H; Saeedian B; Pasebani Y; Babajani N; Pashapour Yeganeh A; Bahirai P; Navid H; Amin A; Samsky MD; Nanna MG; Hosseini K
ESC Heart Fail; 2024 Apr; 11(2):637-648. PubMed ID: 38124239
[TBL] [Abstract][Full Text] [Related]
19. Promise of sodium-glucose co-transporter-2 inhibitors in heart failure with mildly reduced ejection fraction.
Shen X; Shen X
ESC Heart Fail; 2022 Aug; 9(4):2239-2248. PubMed ID: 35642772
[TBL] [Abstract][Full Text] [Related]
20. The Female Sex Confers Different Prognosis in Heart Failure: Same Mortality but More Readmissions.
López-Vilella R; Marqués-Sulé E; Laymito Quispe RDP; Sánchez-Lázaro I; Donoso Trenado V; Martínez Dolz L; Almenar Bonet L
Front Cardiovasc Med; 2021; 8():618398. PubMed ID: 33748194
[No Abstract] [Full Text] [Related]
[Next] [New Search]
